Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study.

Journal of the American Heart Association - 27 May 2015

McDonough Caitrin W, McClure Leslie A, Mitchell Braxton D, Gong Yan, Horenstein Richard B, Lewis Joshua P, Field Thalia S, Talbert Robert L, Benavente Oscar R, Johnson Julie A, Shuldiner Alan R

Abstract excerpt

BACKGROUND: The role of the CYP2C19 genotype on clopidogrel efficacy has been studied widely, with data suggesting reduced clopidogrel efficacy in loss-of-function variant carriers taking clopidogrel after percutaneous coronary intervention; however, data are limited regarding the association between CYP2C19 genetic variants and outcomes in stroke patients. We investigated whether CYP2C19 metabolizer status...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clopidogrel
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Platelet Aggregation Inhibitors

Share to Recurrence

Share to Secondary Prevention

Share to Stroke

Share to Ticlopidine

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 26019129
DOI: 10.1161/JAHA.114.001652
PMCID: PMC4599525

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study.PMID 26019129Read ↗

The role of CYP2C19 genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack.Semantic proximity Read ↗

Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.Semantic proximity Read ↗

Efficacy of Clopidogrel for Prevention of Stroke Based on CYP2C19 Allele Status in the POINT Trial.Semantic proximity Read ↗

Clopidogrel preventive effect based on cytochrome P450 2C19 genotype in ischaemic stroke: protocol for multicentre observational study.Semantic proximity Read ↗

Investigating CYP2C19 loss-of-function allele statuses and their association with stroke of different etiologies in a Taiwanese populationSemantic proximity Read ↗

Efficacy of dual antiplatelet therapy after ischemic stroke according to hsCRP levels and CYP2C19 genotype.Semantic proximity Read ↗

Protocol for the comparison of triflusal and clopidogrel in secondary prevention of stroke based on cytochrome P450 2C19 genotyping (MASETRO study): A multicenter, randomized, open-label, parallel-group trial.Semantic proximity Read ↗

Impact of Cytochrome P450 2C19 Polymorphism on Ischemic Stroke PrognosisSemantic proximity Read ↗

Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Genotype-guided ticagrelor/prasugrel versus clopidogrel therapy in stroke patients with CYP2C19 loss of function alleles: a systematic review and meta-analysis.Semantic proximity Read ↗

Genotype-Guided Dual Antiplatelet Therapy in Minor Stroke or Transient Ischemic Attack With a Single Small Subcortical Infarction.Semantic proximity Read ↗

CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.